Skip to main content

Articles

Page 5 of 102

  1. The role of nuclear receptors in both the aetiology and treatment of breast cancer is exemplified by the use of the oestrogen receptor (ER) as a prognostic marker and treatment target. Treatments targeting the...

    Authors: Tram B. Doan, Vanessa Cheung, Colin D. Clyne, Heidi N. Hilton, Natalie Eriksson, Morag J. Young, John W. Funder, George E. O. Muscat, Peter J. Fuller, Christine L. Clarke and J. Dinny Graham
    Citation: Breast Cancer Research 2020 22:122
  2. Metaplastic breast cancer (MpBC) is an exceedingly rare breast cancer variant that is therapeutically challenging and aggressive. MpBC is defined by the histological presence of at least two cellular types, ty...

    Authors: Tejaswini P. Reddy, Roberto R. Rosato, Xiaoxian Li, Stacy Moulder, Helen Piwnica-Worms and Jenny C. Chang
    Citation: Breast Cancer Research 2020 22:121
  3. Treatment options for triple-negative breast cancer remain limited. Activation of the PI3K pathway via loss of PTEN and/or INPP4B is common. Buparlisib is an orally bioavailable, pan-class I PI3K inhibitor. We ev...

    Authors: Ana C. Garrido-Castro, Cristina Saura, Romualdo Barroso-Sousa, Hao Guo, Eva Ciruelos, Begoña Bermejo, Joaquin Gavilá, Violeta Serra, Aleix Prat, Laia Paré, Pamela Céliz, Patricia Villagrasa, Yisheng Li, Jennifer Savoie, Zhan Xu, Carlos L. Arteaga…
    Citation: Breast Cancer Research 2020 22:120
  4. We performed a systematic review and meta-analysis to evaluate the prognostic significance of 18F-FDG PET and PET/CT for evaluation of responses to neoadjuvant chemotherapy (NAC) in breast cancer patients.

    Authors: Sangwon Han and Joon Young Choi
    Citation: Breast Cancer Research 2020 22:119
  5. Although anti-inflammatory agents could theoretically have anticancer properties, results from cohort studies on nonsteroidal anti-inflammatory drugs (NSAIDs) and breast cancer (BC) risk are inconsistent.

    Authors: Manon Cairat, Marie Al Rahmoun, Marc J. Gunter, Gianluca Severi, Laure Dossus and Agnès Fournier
    Citation: Breast Cancer Research 2020 22:118
  6. Although breast cancer mortality is a result of distant recurrences associated with the establishment of tumor dormancy, current clinical practice guidelines recommend a wait and watch approach for tumor recur...

    Authors: Hussein F. Aqbi, Cara Coleman, Melika Zarei, Saeed H. Manjili, Laura Graham, Jennifer Koblinski, Chunquing Guo, Yibin Xie, Georgi Guruli, Harry D. Bear, Michael O. Idowu, Mehran Habibi, Xiang-Yang Wang and Masoud H. Manjili
    Citation: Breast Cancer Research 2020 22:116
  7. Obesity is a risk factor for breast cancer (BC) development, recurrence, and death. In view of this, we aimed to investigate the clinical value of obesity in BC patients treated with anti-HER2 therapies in the...

    Authors: Serena Di Cosimo, Luca Porcu, Dominique Agbor-tarh, Saverio Cinieri, Maria Alice Franzoi, Maria Carmen De Santis, Cristina Saura, Jens Huober, Debora Fumagalli, Miguel Izquierdo, Martine Piccart, Maria Grazia Daidone and Evandro de Azambuja
    Citation: Breast Cancer Research 2020 22:115
  8. The global observational BREAKOUT study investigated germline BRCA mutation (gBRCAm) prevalence in a population of patients with human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (...

    Authors: Joyce O’Shaughnessy, Christine Brezden-Masley, Marina Cazzaniga, Tapashi Dalvi, Graham Walker, James Bennett and Shozo Ohsumi
    Citation: Breast Cancer Research 2020 22:114
  9. Immunotherapy has recently been proposed as a promising treatment to stop breast cancer (BrCa) progression and metastasis. However, there has been limited success in the treatment of BrCa with immune checkpoin...

    Authors: Benjamin Heng, Ayse A. Bilgin, David B. Lovejoy, Vanessa X. Tan, Heloisa H. Milioli, Laurence Gluch, Sonia Bustamante, Tharani Sabaretnam, Pablo Moscato, Chai K. Lim and Gilles J. Guillemin
    Citation: Breast Cancer Research 2020 22:113
  10. Earlier age at menarche is an established risk factor for breast cancer. While age at menarche has been fairly stable over the past half-century, age at breast development (thelarche) has continued to decrease...

    Authors: Mandy Goldberg, Aimee A. D’Aloisio, Katie M. O’Brien, Shanshan Zhao and Dale P. Sandler
    Citation: Breast Cancer Research 2020 22:112
  11. When chemotherapy is indicated in patients with early breast cancer, regimens that contain anthracyclines and taxanes are established standard treatments. Gemcitabine has shown promising effects on the respons...

    Authors: Amelie de Gregorio, Lothar Häberle, Peter A. Fasching, Volkmar Müller, Iris Schrader, Ralf Lorenz, Helmut Forstbauer, Thomas W. P. Friedl, Emanuel Bauer, Nikolaus de Gregorio, Miriam Deniz, Visnja Fink, Inga Bekes, Ulrich Andergassen, Andreas Schneeweiss, Hans Tesch…
    Citation: Breast Cancer Research 2020 22:111
  12. An amendment to this paper has been published and can be accessed via the original article.

    Authors: Arik Drucker, Byong Hoon Yoo, Iman Aftab Khan, Dongsic Choi, Laura Montermini, Xiaoyang Liu, Sanja Jovanovic, Tallal Younis and Kirill V. Rosen
    Citation: Breast Cancer Research 2020 22:110

    The original article was published in Breast Cancer Research 2020 22:105

  13. Insulin-like growth factor 1 (IGF-1) and binding protein 3 (IGFBP-3) are associated with breast cancer in women at average risk of cancer. Less is known whether these biomarkers also predict risk in women with...

    Authors: Kelsey R. Monson, Mandy Goldberg, Hui-Chen Wu, Regina M. Santella, Wendy K. Chung and Mary Beth Terry
    Citation: Breast Cancer Research 2020 22:109
  14. The BRCA1 c.3331_3334delCAAG founder mutation has been reported in hereditary breast and ovarian cancer families from multiple Hispanic groups. We aimed to evaluate BRCA1 c.3331_3334delCAAG haplotype diversity in...

    Authors: Anna Marie De Asis Tuazon, Paul Lott, Mabel Bohórquez, Jennyfer Benavides, Carolina Ramirez, Angel Criollo, Ana Estrada-Florez, Gilbert Mateus, Alejandro Velez, Jenny Carmona, Justo Olaya, Elisha Garcia, Guadalupe Polanco-Echeverry, Jacob Stultz, Carolina Alvarez, Teresa Tapia…
    Citation: Breast Cancer Research 2020 22:108
  15. The breast cancer genome dynamically evolves during malignant progression and recurrence. We investigated the genomic profiles of primary early-stage breast cancers and matched relapses to elucidate the molecu...

    Authors: Caterina Fumagalli, Alberto Ranghiero, Sara Gandini, Federica Corso, Sergio Taormina, Elisa De Camilli, Alessandra Rappa, Davide Vacirca, Giuseppe Viale, Elena Guerini-Rocco and Massimo Barberis
    Citation: Breast Cancer Research 2020 22:107
  16. Breast cancer survivors (BCS) may have increased risk of hypothyroidism, but risk according to treatment modality is unclear. We estimated the incidence of hypothyroidism in women with breast cancer, and accor...

    Authors: Anne Mette Falstie-Jensen, Buket Ö. Esen, Anders Kjærsgaard, Ebbe L. Lorenzen, Jeanette D. Jensen, Kristin V. Reinertsen, Olaf M. Dekkers, Marianne Ewertz and Deirdre P. Cronin-Fenton
    Citation: Breast Cancer Research 2020 22:106
  17. ErbB2/HER2 oncoprotein often drives breast cancers (BCs) which are treated with the anti-ErbB2 antibody trastuzumab. The efficacy of trastuzumab-based metastatic BC therapies is routinely assessed by imaging s...

    Authors: Arik Drucker, Byong Hoon Yoo, Iman Aftab Khan, Dongsic Choi, Laura Montermini, Xiaoyang Liu, Sanja Jovanovic, Tallal Younis and Kirill V. Rosen
    Citation: Breast Cancer Research 2020 22:105

    The Correction to this article has been published in Breast Cancer Research 2020 22:110

  18. Systemic inflammation may play a role in shaping breast composition, one of the strongest risk factors for breast cancer. Pubertal development presents a critical window of breast tissue susceptibility to exog...

    Authors: Karin B. Michels, Kristen Keller, Ana Pereira, Claire E. Kim, José L. Santos, John Shepherd, Camila Corvalan and Alexandra M. Binder
    Citation: Breast Cancer Research 2020 22:104
  19. Sunitinib, a receptor tyrosine kinase (RTK) inhibitor that targets multiple receptors such as vascular endothelial growth factor receptors (VEGFRs), was approved for cancer treatment in 2006. However, it was u...

    Authors: Denian Wang, Fei Xiao, Zhongxue Feng, Min Li, Lingmiao Kong, Luping Huang, Yong’gang Wei, Hongyu Li, Fei Liu, Haili Zhang and Wei Zhang
    Citation: Breast Cancer Research 2020 22:103
  20. Breast cancer arises within specific regions in the human breast referred to as the terminal duct lobular units (TDLUs). These are relatively dynamic structures characterized by sex hormone driven cyclic epith...

    Authors: Mikkel Morsing, Jiyoung Kim, René Villadsen, Nadine Goldhammer, Abbas Jafari, Moustapha Kassem, Ole William Petersen and Lone Rønnov-Jessen
    Citation: Breast Cancer Research 2020 22:102
  21. A decrease in breast density due to tamoxifen preventive therapy might indicate greater benefit from the drug. It is not known whether mammographic density continues to decline after 1 year of therapy, or whet...

    Authors: Adam R. Brentnall, Ruth Warren, Elaine F. Harkness, Susan M. Astley, Julia Wiseman, Jill Fox, Lynne Fox, Mikael Eriksson, Per Hall, Jack Cuzick, D. Gareth Evans and Anthony Howell
    Citation: Breast Cancer Research 2020 22:101
  22. Exposure to certain outdoor air pollutants may be associated with a higher risk of breast cancer, though potential underlying mechanisms are poorly understood. We examined whether outdoor air pollution was ass...

    Authors: Nicole M. Niehoff, Alexander P. Keil, Rena R. Jones, Shaoqi Fan, Gretchen L. Gierach and Alexandra J. White
    Citation: Breast Cancer Research 2020 22:100
  23. Well-tolerated and commonly used medications are increasingly assessed for reducing breast cancer risk. These include metformin and statins, both linked to reduced hormone availability and cell proliferation o...

    Authors: Erica J. Lee Argov, Teofilia Acheampong, Mary Beth Terry, Carmen B. Rodriguez, Mariangela Agovino, Ying Wei, Shweta Athilat and Parisa Tehranifar
    Citation: Breast Cancer Research 2020 22:99
  24. Previous cohort studies have reported plasma TK1 activity (pTKa) as a potential prognostic biomarker in estrogen receptor-positive (ER+) HER2-negative (HER2−) metastatic breast cancer (MBC). In this prospectiv...

    Authors: Luc Cabel, Dan Rosenblum, Florence Lerebours, Etienne Brain, Delphine Loirat, Mattias Bergqvist, Paul Cottu, Anne Donnadieu, Anne Bethune, Nicolas Kiavue, Manuel Rodrigues, Jean-Yves Pierga, Marie-Laure Tanguy and François-Clément Bidard
    Citation: Breast Cancer Research 2020 22:98
  25. Elacestrant is an oral selective estrogen receptor (ER) degrader. This phase 1b open-label, non-randomized study (RAD1901-106) was initiated to determine the effect of elacestrant on the availability of ER in ...

    Authors: Agnes Jager, Elisabeth G. E. de Vries, C. Willemien Menke-van der Houven van Oordt, Patrick Neven, Clasina M. Venema, Andor W. J. M. Glaudemans, Yamei Wang, Rebecca G. Bagley, Maureen G. Conlan and Philippe Aftimos
    Citation: Breast Cancer Research 2020 22:97
  26. Use of aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) has been hypothesized to be associated with reduced risk of breast cancer; however, results of epidemiological studies have been mixed. F...

    Authors: Kimberly A. Bertrand, Traci N. Bethea, Hanna Gerlovin, Patricia F. Coogan, Lauren Barber, Lynn Rosenberg and Julie R. Palmer
    Citation: Breast Cancer Research 2020 22:96
  27. Mammographic density (MD) is a strong risk factor for breast cancer. We examined how endogenous plasma hormones are associated with average MD area (cm2) and annual MD change (cm2/year).

    Authors: Marike Gabrielson, Shadi Azam, Elina Hardell, Madeleine Holm, Kumari A. Ubhayasekera, Mikael Eriksson, Magnus Bäcklund, Jonas Bergquist, Kamila Czene and Per Hall
    Citation: Breast Cancer Research 2020 22:95
  28. Obesity and low muscle mass are associated with worse outcomes of breast cancer patients. We conducted a controlled trial to study the impact of a ketogenic diet (KD) based on natural foods versus an unspecifi...

    Authors: Rainer J. Klement, Colin E. Champ, Ulrike Kämmerer, Petra S. Koebrunner, Kelley Krage, Gabriele Schäfer, M. Weigel and Reinhart A. Sweeney
    Citation: Breast Cancer Research 2020 22:94
  29. To investigate if baseline and/or changes in contralateral background parenchymal enhancement (BPE) and fibroglandular tissue (FGT) measured on magnetic resonance imaging (MRI) and mammographic breast density ...

    Authors: Roberto Lo Gullo, Isaac Daimiel, Carolina Rossi Saccarelli, Almir Bitencourt, Varadan Sevilimedu, Danny F. Martinez, Maxine S. Jochelson, Elizabeth A. Morris, Jeffrey S. Reiner and Katja Pinker
    Citation: Breast Cancer Research 2020 22:93
  30. Metaplastic breast carcinoma (MBC) is a rare histological type of breast cancer, which commonly shows resistance to standard therapies and is associated with poor prognosis. The immune microenvironment in MBC ...

    Authors: Xue Chao, Lili Liu, Peng Sun, Xia Yang, Mei Li, Rongzhen Luo, Yuhua Huang, Jiehua He and Jingping Yun
    Citation: Breast Cancer Research 2020 22:92
  31. Metastatic breast cancer remains incurable. Next-generation sequencing (NGS) offers the ability to identify actionable genomic alterations in tumours which may then be matched with targeted therapies, but the ...

    Authors: Courtney T. van Geelen, Peter Savas, Zhi Ling Teo, Stephen J. Luen, Chen-Fang Weng, Yi-An Ko, Keilly S. Kuykhoven, Franco Caramia, Roberto Salgado, Prudence A. Francis, Sarah-Jane Dawson, Stephen B. Fox, Andrew Fellowes and Sherene Loi
    Citation: Breast Cancer Research 2020 22:91

    The Correction to this article has been published in Breast Cancer Research 2022 24:50

  32. The Oncotype DX 21-gene Recurrence Score is a genomic-based algorithm that guides adjuvant chemotherapy treatment decisions for women with early-stage, oestrogen receptor (ER)-positive breast cancer. However, ...

    Authors: Sarah M. Bernhardt, Pallave Dasari, Joseph Wrin, Wendy Raymond, Suzanne Edwards, David Walsh, Amanda R. Townsend, Timothy J. Price and Wendy V. Ingman
    Citation: Breast Cancer Research 2020 22:90
  33. Combined targeting of CDK4/6 and ER is now the standard of care for patients with advanced ER+/HER2− breast cancer. However, acquired resistance to these therapies frequently leads to disease progression. As s...

    Authors: Neil A. O’Brien, Martina S. J. McDermott, Dylan Conklin, Tong Luo, Raul Ayala, Suruchi Salgar, Kevin Chau, Emmanuelle DiTomaso, Naveen Babbar, Faye Su, Alex Gaither, Sara A. Hurvitz, Ronald Linnartz, Kristine Rose, Samit Hirawat and Dennis J. Slamon
    Citation: Breast Cancer Research 2020 22:89
  34. Perinatal factors have been associated with some adult health outcomes, but have not been well studied in young-onset breast cancer. We aimed to evaluate the association between young-onset breast cancer and peri...

    Authors: Mary V. Diaz-Santana, Katie M. O’Brien, Aimee A. D’Aloisio, Gloria Regalado, Dale P. Sandler and Clarice R. Weinberg
    Citation: Breast Cancer Research 2020 22:88
  35. Resistance to endocrine therapy is a major clinical challenge in the management of oestrogen receptor (ER)-positive breast cancer. In this setting, p53 is frequently wildtype and its activity may be suppressed...

    Authors: Neil Portman, Heloisa H. Milioli, Sarah Alexandrou, Rhiannon Coulson, Aliza Yong, Kristine J. Fernandez, Kee Ming Chia, Ensar Halilovic, Davendra Segara, Andrew Parker, Sue Haupt, Ygal Haupt, Wayne D. Tilley, Alex Swarbrick, C. Elizabeth Caldon and Elgene Lim
    Citation: Breast Cancer Research 2020 22:87
  36. Tumor-derived extracellular vesicles (tdEVs) and circulating tumor cells (CTCs) in the blood of metastatic cancer patients associate with poor outcomes. In this study, we explored the human epidermal growth fa...

    Authors: Afroditi Nanou, Leonie Laura Zeune, Francois-Clement Bidard, Jean-Yves Pierga and Leonardus Wendelinus Mathias Marie Terstappen
    Citation: Breast Cancer Research 2020 22:86
  37. Invasive lobular carcinoma (ILC) accounts for 10–15% of primary breast cancers and is typically estrogen receptor alpha positive (ER+) and ERBB2 non-amplified. Somatic mutations in ERBB2/3 are emerging as a tract...

    Authors: Sasagu Kurozumi, Mansour Alsaleem, Cíntia J. Monteiro, Kartikeya Bhardwaj, Stacey E. P. Joosten, Takaaki Fujii, Ken Shirabe, Andrew R. Green, Ian O. Ellis, Emad A. Rakha, Nigel P. Mongan, David M. Heery, Wilbert Zwart, Steffi Oesterreich and Simon J. Johnston
    Citation: Breast Cancer Research 2020 22:85
  38. Endocrine therapy is the most common treatment for estrogen receptor (ER)-positive breast cancer, but its effectiveness is limited by high rates of primary and acquired resistance. There are likely many geneti...

    Authors: Li Li, Ling Lin, Jamunarani Veeraraghavan, Yiheng Hu, Xian Wang, Sanghoon Lee, Ying Tan, Rachel Schiff and Xiao-Song Wang
    Citation: Breast Cancer Research 2020 22:84
  39. Limited data are available regarding the use of nab-paclitaxel in older patients with breast cancer. A weekly schedule is recommended, but there is a paucity of evidence regarding the optimal dose. We evaluate...

    Authors: Laura Biganzoli, Saverio Cinieri, Rossana Berardi, Rebecca Pedersini, Amelia McCartney, Alessandro Marco Minisini, Elena Rota Caremoli, Simon Spazzapan, Emanuela Magnolfi, Antonella Brunello, Emanuela Risi, Raffaella Palumbo, Silvana Leo, Marco Colleoni, Sara Donati, Sabino De Placido…
    Citation: Breast Cancer Research 2020 22:83
  40. Breast cancer cells invading the connective tissues outside the mammary lobule or duct immerse in a reservoir of extracellular matrix (ECM) that is structurally and biochemically distinct from that of their si...

    Authors: Kelsey F. Ruud, William C. Hiscox, Ilhan Yu, Roland K. Chen and Weimin Li
    Citation: Breast Cancer Research 2020 22:82
  41. Previous studies have identified and validated a risk-associated Active transcriptome phenotype commonly expressed in the cancer-adjacent and histologically normal epithelium, stroma, and adipose containing perit...

    Authors: Taekyu Kang, Christina Yau, Christopher K. Wong, John Z. Sanborn, Yulia Newton, Charlie Vaske, Stephen C. Benz, Gregor Krings, Roman Camarda, Jill E. Henry, Josh Stuart, Mark Powell and Christopher C. Benz
    Citation: Breast Cancer Research 2020 22:81
  42. The estrogen receptor (ER)-positive breast cancer represents over 80% of all breast cancer cases. Even though adjuvant hormone therapy with tamoxifen (TMX) is saving lives of patients with ER-positive breast c...

    Authors: Madhurendra Singh, Xiaolei Zhou, Xinsong Chen, Gema Sanz Santos, Sylvain Peuget, Qing Cheng, Ali Rihani, Elias S. J. Arnér, Johan Hartman and Galina Selivanova
    Citation: Breast Cancer Research 2020 22:80
  43. We previously showed that BRCA-like profiles can be used to preselect individuals with the highest risk of carrying BRCA mutations but could also indicate which patients would benefit from double-strand break ind...

    Authors: Esther H. Lips, Anne Benard-Slagter, Mark Opdam, Caroline E. Scheerman, Jelle Wesseling, Frans B. L. Hogervorst, Sabine C. Linn, Suvi Savola and Petra M. Nederlof
    Citation: Breast Cancer Research 2020 22:79
  44. Previous studies of fatty acids and breast cancer risk have shown mixed results, which may be due in part to tumor heterogeneity. Prior research has also illustrated an important role of specific fatty acids i...

    Authors: Emma E. McGee, Claire H. Kim, Molin Wang, Donna Spiegelman, Daniel G. Stover, Yujing J. Heng, Laura C. Collins, Gabrielle M. Baker, Maryam S. Farvid, Pepper Schedin, Sonali Jindal, Rulla M. Tamimi and A. Heather Eliassen
    Citation: Breast Cancer Research 2020 22:78
  45. For patients with locally advanced estrogen receptor or progesterone receptor-positive breast cancer, neoadjuvant endocrine therapy (NET) facilitates down-staging of the tumor and increased rates of breast-con...

    Authors: Lauren I. Madigan, Phuong Dinh and J. Dinny Graham
    Citation: Breast Cancer Research 2020 22:77
  46. Early luminal breast cancer (BC) represents 70% of newly diagnosed BC cases. Among them, small (under 2 cm) BC without lymph node metastasis (classified as T1N0) have been rarely studied, as their prognosis is...

    Authors: Claire Bonneau, Antoine Eliès, Yann Kieffer, Brigitte Bourachot, Sylvain Ladoire, Floriane Pelon, Delphine Hequet, Jean-Marc Guinebretière, Christophe Blanchet, Anne Vincent-Salomon, Roman Rouzier and Fatima Mechta-Grigoriou
    Citation: Breast Cancer Research 2020 22:76
  47. PGRMC1 (progesterone receptor membrane component 1) is a highly conserved heme binding protein, which is overexpressed especially in hormone receptor-positive breast cancer and plays an important role in breas...

    Authors: Hannah Asperger, Nadia Stamm, Berthold Gierke, Michael Pawlak, Ute Hofmann, Ulrich M. Zanger, Annamaria Marton, Robert L. Katona, Andrea Buhala, Csaba Vizler, Jan-Philipp Cieslik, Eugen Ruckhäberle, Dieter Niederacher, Tanja Fehm, Hans Neubauer and Marina Ludescher
    Citation: Breast Cancer Research 2020 22:75

    The Correction to this article has been published in Breast Cancer Research 2021 23:13

  48. Cancer cells are known to display varying degrees of metastatic propensity, but the molecular basis underlying such heterogeneity remains unclear. Our aims in this study were to (i) elucidate prognostic subtyp...

    Authors: Amin Emad, Tania Ray, Tor W. Jensen, Meera Parat, Rachael Natrajan, Saurabh Sinha and Partha S. Ray
    Citation: Breast Cancer Research 2020 22:74
  49. Studies on tumor-secreted microRNAs point to a functional role of these in cellular communication and reprogramming of the tumor microenvironment. Uptake of tumor-secreted microRNAs by neighboring cells may re...

    Authors: Thilde Terkelsen, Francesco Russo, Pavel Gromov, Vilde Drageset Haakensen, Søren Brunak, Irina Gromova, Anders Krogh and Elena Papaleo
    Citation: Breast Cancer Research 2020 22:73

Annual Journal Metrics